Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK).

Full DD Report for MACK

You must become a subscriber to view this report.


Recent News from (NASDAQ: MACK)

Merrimack Pharmaceuticals' (MACK) CEO Richard Peters on Q1 2018 Results - Earnings Call Transcript
Merrimack Pharmaceuticals (MACK) Q1 2018 Earnings Conference Call May 08, 2018 08:30 AM ET Executives Geoff Grande - Senior Director, Communications Richard Peters - President and CEO Sergio Santillana - CMO Jean Franchi - CFO Analysts Laura Christianson - Cowen Presen...
Source: SeekingAlpha
Date: May, 08 2018 09:52
Merrimack Reports First Quarter 2018 Financial Results
CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its first quarter 2018 financial results for the period ended March 31, 2018 . ...
Source: PR Newswire
Date: May, 08 2018 06:25
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
CAMBRIDGE, Mass. , May 1, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.   The company will provid...
Source: PR Newswire
Date: May, 01 2018 07:00
Merrimack Pharmaceuticals Potential Catalyst A Likely Bust
Merrimack Pharmaceuticals (MACK) is a small capitalization, clinical-stage pharmaceutical company focused on cancer therapies. Merrimack once was a commercial company, based on FDA approval of Onivyde, but it sold the rights to the drug and issued a special dividend to investors. Since then it...
Source: SeekingAlpha
Date: April, 19 2018 12:19
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. , April 9, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present preclinical data at the 2018 American Association for Cancer Research (AACR) A...
Source: PR Newswire
Date: April, 09 2018 07:30
Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail - Fundamental Analysis, Key Performance Indications
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Monroe Capital Corporatio...
Source: GlobeNewswire
Date: April, 04 2018 08:15
Wired News - Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer
Stock Monitor: Dermira Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 14, 2018 / Active-Investors.com has just released a free research report on Merrimack Pharma, Inc. (NASDAQ: MACK ). If you want access to this report all you need to do is sign up now by clicking the follo...
Source: ACCESSWIRE IA
Date: March, 14 2018 07:30
Your Daily Pharma Scoop: Portola's New Interim Data, Lantheus Announces Promising Data For LMI 1195, Kura Tumbles On Update
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today, we will discuss Portola Pharmaceuticals (PTLA), which saw a pullback after announcing new interim data from late-stage study of AndexXa. Earlier this month, PTLA had seen a huge sell-off amid concerns that the potential...
Source: SeekingAlpha
Date: March, 13 2018 17:27
Merrimack Pharma down 10% on expanded enrollment in mid-stage study of MM-121
Thinly traded micro cap Merrimack Pharmaceuticals ( MACK -9.8% ) slips on almost double normal volume, albeit on turnover of only 224K shares, in reaction to its planned enrollment increase in the Phase 2 SHERLOC study evaluating MM-121 (seribantumab) in patients heregulin-positive non...
Source: SeekingAlpha
Date: March, 12 2018 14:31
Midday Gainers / Losers (3/12/2018)
Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 12 2018 12:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-248.648.4758.658.3651,490
2018-05-238.698.56758.888.528438,810
2018-05-228.698.668.798.6446,128
2018-05-218.828.608.828.5741,365
2018-05-188.878.758.908.6939,755

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2418,00933,13054.3586Short
2018-05-236,68515,87742.1049Short
2018-05-229,79118,79352.0992Short
2018-05-216,25813,32146.9785Short
2018-05-184,16512,64732.9327Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MACK.


About Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

Logo for Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: MACK)

      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Proxy soliciting materials. Revised preliminary material
      Filing Type: PRER14AFiling Source: edgar
      Filing Date: April, 26 2018
      Preliminary proxy statement providing notification matters to be brought to a vote
      Filing Type: PRE 14AFiling Source: edgar
      Filing Date: April, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: MACK)

      Daily Technical Chart for (NASDAQ: MACK)


      Stay tuned for daily updates and more on (NASDAQ: MACK)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: MACK)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MACK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of MACK and does not buy, sell, or trade any shares of MACK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/